2006
DOI: 10.3892/ijo.29.4.903
|View full text |Cite
|
Sign up to set email alerts
|

OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer

Abstract: Abstract. OY-TES-1 is a novel target that belongs to the family of 'cancer/testis' (CT) antigens. Our goal was to examine the expression and immunogenicity of OY-TES-1 in epithelial ovarian cancer (EOC) to determine its potential as a target for vaccine therapy. OY-TES-1 expression was determined by one-step reverse transcriptase PCR on 100 EOC samples, 5 EOC cell lines, and a panel of normal tissues. Immunohistochemistry (IHC) was performed on the same panel of EOC tissues. Sera from a sub-group of patients w… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
29
1

Year Published

2010
2010
2024
2024

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 24 publications
(30 citation statements)
references
References 17 publications
0
29
1
Order By: Relevance
“…Whereas some studies used undefined protein extracts from tumor lysates (11,14,(28)(29)(30), others focused on limited numbers of candidate tumor antigens (24,25). To our knowledge, only two studies have performed a large-scale profiling of autoantibodies related to cancer using the extensive panel of human antigens present on ProtoArrays, one study probing with 12 colorectal cancer sera and 8 control sera (2), and the other probing with 30 ovarian cancer sera and 30 healthy controls (9).…”
Section: Discussionmentioning
confidence: 99%
“…Whereas some studies used undefined protein extracts from tumor lysates (11,14,(28)(29)(30), others focused on limited numbers of candidate tumor antigens (24,25). To our knowledge, only two studies have performed a large-scale profiling of autoantibodies related to cancer using the extensive panel of human antigens present on ProtoArrays, one study probing with 12 colorectal cancer sera and 8 control sera (2), and the other probing with 30 ovarian cancer sera and 30 healthy controls (9).…”
Section: Discussionmentioning
confidence: 99%
“…In the human, pig, and mouse, ACRBP is known to be tyrosine phosphorylated during sperm capacitation [8][9][10], leading to the possibility that the partitioning of acrosomal components in the soluble, matrix, and acrosomal membrane compartments of the acrosome may be regulated by the phosphorylation status of ACRBP [9]. Moreover, ACRBP has been identified as a member of the cancer/testis antigen family; ACRBP is normally expressed only in the testis, but it is also expressed in a wide range of different tumor types, including bladder, breast, liver, and lung carcinomas [11][12][13]. Despite the importance of ACRBP in male gamete and cancer cells, the function of ACRBP has been poorly understood thus far.…”
Section: Introductionmentioning
confidence: 98%
“…ACRBP also has been identified as a member of the cancer/testis antigen family; ACRBP is normally expressed exclusively in the testis, but is also expressed in a wide range of different tumor types, including bladder, breast, liver, and lung carcinomas (15)(16)(17). Mammalian ACRBP is initially synthesized as a ∼60-kDa precursor protein (ACRBP-W) in spermatogenic cells, and the 32-kDa mature ACRBP (ACRBP-C) is posttranslationally produced by removal of the N-terminal half of the precursor ACRBP-W during spermatogenesis and/or epididymal maturation of sperm (14,18).…”
mentioning
confidence: 99%